October 18, 2018Journal of Antimicrobial ChemotherapyOpen Access

In vitroactivities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistantPseudomonas aeruginosaandAcinetobacter baumannii, andStenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan

View Full Paper

Ask AI

Bookmark

Abstract

Cefiderocol exhibited more potent in vitro activity than ceftolozane/tazobactam and ceftazidime/avibactam against imipenem-resistant P. aeruginosa, imipenem-resistant A. baumannii and S. maltophilia isolates.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Hsueh et al. (2018) studied this question.

synapsesocial.com/papers/69d85c25c025a7c015beda9f https://doi.org/10.1093/jac/dky425

View Full Paper

Ask AI

Bookmark

In vitroactivities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistantPseudomonas aeruginosaandAcinetobacter baumannii, andStenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan

Abstract

Discussion

Cite This Study

In vitroactivities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistantPseudomonas aeruginosaandAcinetobacter baumannii, andStenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan

Abstract

Discussion

Cite This Study

Also Consider

Also Consider